Stockreport

Theriva™ Biologics Reports Third Quarter 2025 Operational Highlights and Financial Results

Theriva Biologics, Inc.  (TOVX) 
PDF - Expanded data for VCN-01 (zabilugene almadenorepvec) in metastatic pancreatic ductal adenocarcinoma (PDAC) from the VIRAGE Phase 2b trial presented at the European Soc [Read more]